Advertisement
U.S. markets closed
Advertisement

Merck KGaA (MRK.DE)

XETRA - XETRA Delayed Price. Currency in EUR
161.950.00 (0.00%)
At close: 05:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close161.95
Open162.00
Bid162.90 x 6700
Ask162.95 x 11200
Day's Range160.80 - 164.00
52 Week Range135.00 - 202.80
Volume295,709
Avg. Volume317,911
Market Cap70.412B
Beta (5Y Monthly)0.70
PE Ratio (TTM)24.32
EPS (TTM)6.66
Earnings DateNov 09, 2023
Forward Dividend & Yield2.20 (1.36%)
Ex-Dividend DateMay 02, 2023
1y Target Est187.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MRK.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 2-Merck KGaA suffers major blow as MS drug fails in late-stage trials

      Germany's Merck KGaA said its experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials, dealing a major blow to the company's growth ambitions. In the Phase III trials, evobrutinib failed to reduce the annualized relapse rate compared to Sanofi's Aubagio in patients with relapsing multiple sclerosis, Merck said in a statement on Tuesday. Merck was seen as ahead of Sanofi, Novartis and Roche in a four-way race to develop more targeted MS drugs in a class known as Bruton’s tyrosine kinase (BTK) inhibitors.

    • Simply Wall St.

      Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 85% Above Its Share Price

      Key Insights The projected fair value for Merck KGaA is €297 based on 2 Stage Free Cash Flow to Equity Current share...

    • Thomson Reuters StreetEvents

      Q3 2023 Exscientia PLC Earnings Call

      Q3 2023 Exscientia PLC Earnings Call